

Technology Appraisal Committee A Interests Register

Topic: Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

Publication Date: 07 May 2026

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Hugo Pedder	TAC Committee Member	Indirect – Financial	<p>Hugo has performed work for Merck Sharp & Dohme in the last 12 months on behalf of his employer, ConnectHEOR, on methodological training (i.e. not related to any specific technology or indication).</p> <p>HP has performed paid statistical consultancy within the last 12 months for Merck Sharp & Dohme on behalf of ConnectHEOR for methodological training unrelated to any specific technology or indication.</p>	12/02/2026 08/12/2025	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.
Dominic Pivonka	TAC A Committee Member	Direct - Financial	Dominic's employer (AbbVie) has a treatment being evaluated for gynaecologic cancers including a Phase 1 which includes recurrent cervical cancers	16/02/2026	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal. / It was agreed that Dominic's declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Patrick de Barr	TAC Committee Member	Indirect – Financial	<p>Patrick is employed by GSK who manufacture a PD1 antibody that competes with pembrolizumab in other disease areas.</p> <p>Patrick works for GSK who have a PD1 monoclonal antibody that is marketed but in a different indication and GSK are not listed as a comparator / competitor in this appraisal</p>	<p>19/02/2026</p> <p>12/12/2025</p>	It was agreed that Patrick's declaration would prevent him from participating in discussions on this appraisal.
Dr Asma Sarwar	Clinical Expert	Indirect – Financial	Dr Sarwar works at UCLH which was the principal site for the INTERLACE trial (use of neoadjuvant chemotherapy prior to chemoradiation in locally advanced cervical cancer). This trial had closed to recruitment before they took up my post as a consultant at UCLH. Dr Sarwar was not involved in patient recruitment or in the publications.	20/01/2025	It was agreed that Dr Sarwar's declaration would not prevent [him/her] from providing expert advice to the committee.
Dr Alexandra Taylor	Clinical Expert	Direct - Financial	<p>Advisory board MSD, Regeneron Jan 2025</p> <p>Council member and Guidelines co-chair: British Gynaecological Cancer Society (2020-current)</p>	10/03/2025	It was agreed that Dr Talyor's declaration would not prevent her from providing expert advice to the committee.